Analysts Issue Forecasts for Cardiovascular Systems, Inc.’s Q1 2024 Earnings (NASDAQ:CSII)

Cardiovascular Systems, Inc. (NASDAQ:CSIIGet Rating) – Oppenheimer issued their Q1 2024 EPS estimates for shares of Cardiovascular Systems in a note issued to investors on Thursday, August 4th. Oppenheimer analyst S. Kalia forecasts that the medical device company will post earnings per share of ($0.14) for the quarter. The consensus estimate for Cardiovascular Systems’ current full-year earnings is ($0.69) per share. Oppenheimer also issued estimates for Cardiovascular Systems’ Q2 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.07) EPS and FY2024 earnings at ($0.44) EPS.

Cardiovascular Systems Stock Up 0.3 %

Cardiovascular Systems stock opened at $16.55 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.58 and a current ratio of 6.05. Cardiovascular Systems has a 52-week low of $13.41 and a 52-week high of $39.37. The firm has a 50 day moving average price of $15.16 and a two-hundred day moving average price of $17.82. The firm has a market cap of $674.99 million, a price-to-earnings ratio of -17.42 and a beta of 0.94.

Cardiovascular Systems (NASDAQ:CSIIGet Rating) last posted its earnings results on Wednesday, May 4th. The medical device company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.03. Cardiovascular Systems had a negative net margin of 15.64% and a negative return on equity of 14.40%. The business had revenue of $56.22 million for the quarter, compared to the consensus estimate of $57.38 million. During the same period last year, the company earned ($0.15) EPS. The firm’s revenue was down 11.1% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CSII. Allspring Global Investments Holdings LLC bought a new stake in shares of Cardiovascular Systems in the 4th quarter valued at $235,000. Yousif Capital Management LLC bought a new stake in shares of Cardiovascular Systems in the 4th quarter valued at $696,000. Qube Research & Technologies Ltd bought a new stake in shares of Cardiovascular Systems in the 4th quarter valued at $789,000. Assenagon Asset Management S.A. increased its stake in shares of Cardiovascular Systems by 403.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 488,299 shares of the medical device company’s stock valued at $9,170,000 after acquiring an additional 391,400 shares in the last quarter. Finally, Duality Advisers LP increased its stake in shares of Cardiovascular Systems by 68.9% in the 4th quarter. Duality Advisers LP now owns 40,183 shares of the medical device company’s stock valued at $755,000 after acquiring an additional 16,388 shares in the last quarter. Institutional investors own 91.24% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Jeffrey S. Points purchased 3,000 shares of the stock in a transaction on Friday, May 20th. The stock was purchased at an average price of $14.50 per share, for a total transaction of $43,500.00. Following the acquisition, the chief financial officer now owns 109,312 shares in the company, valued at $1,585,024. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 3.00% of the company’s stock.

Cardiovascular Systems Company Profile

(Get Rating)

Cardiovascular Systems, Inc, a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.

Featured Articles

Earnings History and Estimates for Cardiovascular Systems (NASDAQ:CSII)

Want More Great Investing Ideas?

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.